community download

Top HTA considerations for orphan drugs

information we require

please check before submitting



Unfortunately the document is not available at this current time, however if you leave your details we'll get it to you as soon as we can.

Please fill in all the information requested. It is very important you enter this information correctly so we can contact you with the document.

Privacy statement »

Manage your email preferences »

Remember my details Information

Information
Remember my details
We place a 'cookie' on your computer so next time you visit us you don't need to fill in all these details

With global orphan drug sales rising almost 10% a year from 2005 to 2011, twice as fast as the market as a whole, the current austerity conscious governments are applying the same pricing scrutiny to orphan drugs. 

But what are the HTA considerations for orphan drugs and future pricing and cost containment to establish and maintain a level that’s going to be sustainable?

Download this ebook and learn about:

  • Rare diseases: the facts
  • Market access challenges for orphan drugs
  • Challenges with endpoint for rare diseases
  • Pricing scrutiny
  • UK reforms